10-Q: America Great Health Reports Increased Sales but Continues to Face Losses in Latest Quarterly Filing

America Great Health's latest quarterly report shows increased sales driven by new products, but the company continues to operate at a loss and faces going concern challenges.

Summary

• America Great Health reported a net loss of $406,325 for the six months ended December 31, 2023, compared to a net loss of $320,875 for the same period in 2022.
• Sales increased to $104,987 for the six months ended December 31, 2023, up from $90,168 in the same period of 2022, primarily due to new product sales.
• The company's operating expenses rose to $325,090 for the six months ended December 31, 2023, compared to $277,998 in 2022, due to increased professional expenses, stock compensation, original issue discount (OID), and interest expenses.
• The company's cash balance was $72,256 as of December 31, 2023, and it had a shareholders' deficit of $4,778,268.
• The company's auditors have raised concerns about its ability to continue as a going concern due to recurring losses and a lack of liquidity.
• The company's cash needs were primarily met by loans and advances from the current majority shareholder.
• The company has a negative working capital of $2,975,664 as of December 31, 2023.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including substantial losses, a going concern warning, and material weaknesses in internal controls. While there is some sales growth, the overall outlook is negative.

Positives

• Sales increased due to the introduction of new products.
• Gross profit increased to $96,285 for the six months ended December 31, 2023, compared to $54,670 for the same period in 2022.

Negatives

• The company continues to operate at a loss, with a net loss of $406,325 for the six months ended December 31, 2023.
• Operating expenses have increased significantly.
• The company has a substantial shareholders' deficit of $4,778,268.
• The company's auditors have raised concerns about its ability to continue as a going concern.
• The company has a negative working capital of $2,975,664.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and a lack of liquidity.
• The company is dependent on loans and advances from its majority shareholder to meet its cash needs.
• The company has material weaknesses in its internal controls, including a lack of a functioning audit committee and insufficient accounting staff.
• The company's long term loans have high interest rates of 16% and 20%.

Future Outlook

The company intends to finance operating costs over the next twelve months with existing cash on hand and advances from the current majority shareholder, and is focused on achieving profitable operations and raising additional capital.

Management Comments

• Management believes that the material weaknesses set forth in above did not have an effect on our financial results.
• Management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Industry Context

The company operates in the healthcare and biotechnology sectors, which are characterized by high research and development costs and long lead times for product development and regulatory approvals. The company's focus on innovative technologies and small molecular drugs aligns with current industry trends, but its financial challenges highlight the risks associated with early-stage companies in these sectors.

Comparison to Industry Standards

• Compared to established pharmaceutical and biotech companies, America Great Health's revenue is very low, and its losses are significant, indicating it is in a very early stage of development.
• Many early-stage biotech companies rely on venture capital and private funding, while America Great Health is primarily funded by loans and advances from its majority shareholder, which is not a typical funding model.
• The company's lack of a functioning audit committee and material weaknesses in internal controls are not in line with industry best practices for public companies.
• The company's high interest rates on long term loans are not typical for established companies in the sector.

Corporate Governance

Related Party Transactions

• The company received $342,831 in advances from its current majority shareholder and repaid $131,680 during the six months ended December 31, 2023.
• As of December 31, 2023, the company owed its current majority shareholder $636,293.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern issues.
• Employees may be impacted by the company's financial challenges and potential restructuring.
• Customers may be affected by the company's ability to continue operations and deliver products.
• Creditors face increased risk due to the company's financial difficulties.

Next Steps

• The company needs to secure additional sources of capital to continue operations.
• The company needs to improve its internal controls and establish a functioning audit committee.
• The company needs to achieve profitable operations to address going concern issues.

Key Dates

Keywords

financial results, net loss, sales growth, operating expenses, going concern, liquidity, shareholders deficit, internal controls, healthcare, biotechnology